1.An overview of the evolution of EV71 vaccine.
Journal of Biomedical Engineering 2010;27(4):933-936
EV71 infection has become a serious public health threat especially among young children. Yet, at present, no specific antiviral drug against EV71 infection is available. A number of scientists are studying various kinds of vaccines, including inactivated vaccine, virus-like particle vaccine, DNA vaccine, synthetic peptide vaccines, and transgenic oral vaccine. This article reviews the recent advancement in the design of various kinds of vaccine against EV71 as well as their prospective usefulness, effectiveness, weakness and developments in the foreground.
Enterovirus A, Human
;
immunology
;
Hand, Foot and Mouth Disease
;
immunology
;
prevention & control
;
Humans
;
Vaccines, Attenuated
;
immunology
;
Vaccines, DNA
;
immunology
;
Vaccines, Inactivated
;
immunology
;
Vaccines, Synthetic
;
immunology
;
Viral Vaccines
;
immunology
2.Advance in research on novel dengue vaccine.
Chinese Journal of Virology 2011;27(3):315-318
3.Progress in new-type vaccines against classical swine fever.
Chunhua WANG ; Yuan SUN ; Huaji QIU
Chinese Journal of Biotechnology 2013;29(7):880-890
Classical swine fever (CSF), an acute and highly contagious disease of swine, is caused by classical swine fever virus. CSF is one of the most devastating diseases to the pig industry worldwide and results in serious economic losses. Currently prophylactic vaccination is still an important strategy for the control of CSF. Live attenuated vaccines (such as C-strain) are safe and effective. However, there are significant changes in the clinical features of CSF, displaying concurrent typical and atypical CSF, and simultaneous inapparent and persistent infections. Immunization failure has been reported frequently and it is difficult to distinguish between wild-type infected and vaccinated animals (DIVA). So there is an urgent need to develop more effective and safer DIVA or marker vaccines for the control of CSF. In this review, some of the most recent advances in new-type vaccines against CSF, including DNA vaccines, live virus-vectored vaccines, protein or peptide-based vaccines, gene-deleted vaccines and chimeric pestivirus-based vaccines, are reviewed and discussed.
Animals
;
Classical Swine Fever
;
prevention & control
;
Classical swine fever virus
;
Swine
;
Vaccination
;
veterinary
;
Vaccines, Attenuated
;
immunology
;
Vaccines, DNA
;
immunology
;
Vaccines, Subunit
;
immunology
;
Viral Vaccines
;
immunology
4.Development of tumor vaccine on gynecologic cancer.
Acta Academiae Medicinae Sinicae 2003;25(4):487-491
The study of tumor vaccine is one of the focus of immunological therapy on malignant gynecologic cancer. All of the ovarian carcinoma vaccine are therapeutic, including cloned antigen vaccine, tumor cell vaccine, genetic engineering tumor cell vaccine, dendritic cell (DC) vaccine, as well as anti-idiotypic vaccine. The therapeutic vaccines based on human papillomavirus (HPV) of cervical cancer are mostly summarized, including polypeptides vaccine, carrier vaccine, fusion protein or chimeric vaccine, and DC vaccine. The preventive vaccine based on HPV of cervical cancer are briefly introduced. As there are only a few reports on endometrial carcinoma vaccine.
Cancer Vaccines
;
biosynthesis
;
immunology
;
Dendritic Cells
;
immunology
;
Female
;
Genetic Engineering
;
Humans
;
Ovarian Neoplasms
;
immunology
;
Papillomaviridae
;
immunology
;
Papillomavirus Infections
;
immunology
;
Uterine Cervical Neoplasms
;
immunology
;
Vaccines, DNA
;
immunology
5.Severe acute respiratory syndrome: vaccine on the way.
Ding-mei ZHANG ; Guo-ling WANG ; Jia-hai LU
Chinese Medical Journal 2005;118(17):1468-1476
Humans
;
Membrane Glycoproteins
;
immunology
;
SARS Virus
;
immunology
;
Severe Acute Respiratory Syndrome
;
prevention & control
;
Spike Glycoprotein, Coronavirus
;
Vaccines, DNA
;
immunology
;
Vaccines, Inactivated
;
immunology
;
Vaccines, Synthetic
;
immunology
;
Viral Envelope Proteins
;
immunology
;
Viral Vaccines
;
immunology
;
Virion
;
immunology
6.Pilot-scale production and quality control of multiepitope hepatitis B virus DNA vaccine.
Journal of Southern Medical University 2009;29(1):118-120
OBJECTIVETo establish a method for pilot-scale production and quality control of multiepitope hepatitis B virus (HBV) DNA vaccine (PVAX-HS).
METHODSRecombinant DH5alpha/pVAX-HS was obtained by fed-batch fermentation, and the plasmid was extracted by alkaline lysis and concentrated by ultrafiltration. The plasmid DNA was purified by a three-step column chromatography to obtain the DNA vaccine, and quality control tests were performed on the final product.
RESULTSThe quantity of the fed-batch product reached 50-60 g/L, and the final plasmid output was 1.0 mg per gram of the bacteria. The quality of the DNA vaccine met the requirements for medical use.
CONCLUSIONA simple and stable procedure was established for pilot-scale production of multiepitope HBV DNA vaccine, which allows potential large-scale production of the DNA vaccine.
Epitopes ; immunology ; Hepatitis B Vaccines ; biosynthesis ; genetics ; immunology ; Pilot Projects ; Quality Control ; Vaccines, DNA ; biosynthesis ; genetics ; immunology
7.Influenza DNA vaccine: an update.
Chinese Medical Journal 2004;117(1):125-132
8.Construction and immunogenicity of attenuated Salmonella typhimurium stably harbouring DNA vaccine against Newcastle disease virus.
Zhi-Ming PAN ; Jin-Lin HUANG ; Ning-Ning CHENG ; Yi-Chen CUI ; Meng YOU ; Li-Hua TANG ; Xiao-Ming ZHANG ; Xin-An JIAO ; Xiu-Fan LIU
Chinese Journal of Virology 2008;24(1):41-46
The fusion protein (F) gene of Newcastle disease virus was amplified by polymerase chain reaction (PCR) from the recombinant plasmid pVAX1-F, and subcloned into eukaryotic expression vector pmcDNA3. 1+. The F gene was identified by sequencing. The recombinant plasmid was transformed into attenuated Salmonella typhimurium SL7207, and the recombinant was designated as SL7207 (pmcDNA3. 1-F). In vitro and in vivo experiments showed that the plasmid stability of pmcDNA3. 1-F was apparently higher than that of pcDNA3. 1-F in SL7207. In order to compare the immune response induced by these two re combinant bacteria, BALB/c mice were immunized orally with them at the dosage of 2 x 10(9) CFU respectively. Both SL7207(pcDNA3. 1-F) and SL7207(pmcDNA3. 1-F) initiated F-specific serum and mucosal antibodies in immunized mice. Furthermore, 4-day-old SPF chickens were immunized with SL7207(pcDNA3. 1-F) and SL7207(pmcDNA3. 1-F) at the dosage of 5 x 10(9) CFU and boosted two weeks later with the same dosage. Humoral and intestinal mucosal immune responses were observed and their levels were significantly higher than that of negative and positive controls. The result of protective efficacy showed that the chickens immunized with SL7207(pmcDNA3. 1-F) had the protective rate of 70.0%, higher than that of the SL7207 (pcDNA3. 1-F) with 50.0%. In summary, the DNA vaccine delivered by attenuated Salmonella typhimurium has good immunogenicity. A novel mucosal DNA vaccine has been developed and could be useful for controlling the infection and epidemic of Newcastle disease in the poultry.
Animals
;
Chickens
;
Female
;
Immunization
;
Mice
;
Mice, Inbred BALB C
;
Newcastle disease virus
;
immunology
;
Plasmids
;
Salmonella typhimurium
;
genetics
;
Vaccines, Attenuated
;
immunology
;
Vaccines, DNA
;
immunology
;
Viral Vaccines
;
immunology
9.Progress in research on molecular biology and application in dominant antigens ESAT6 and CFP10 of TB vaccine.
Journal of Biomedical Engineering 2012;29(2):392-396
As the dominant antigens, early secreted antigenic target 6 (ESAT6, E6) and culture filtrate protein 10 (CFP10, C10) had once been the focus of tuberculosis (TB) vaccine due to their capability of inducing strong cell immune response in the host. They are also endowed with promising future of prevention against and diagnosis of TB. In this review, we systematically introduce recent research progress of E6 and C10, especially in structure-function, biological characteristics, protein expression and secretion, host immunity and vaccine development, and the prospects of their application are also discussed.
Antigens, Bacterial
;
chemistry
;
genetics
;
immunology
;
Bacterial Proteins
;
chemistry
;
genetics
;
immunology
;
Humans
;
Immunodominant Epitopes
;
immunology
;
Molecular Biology
;
Peptide Fragments
;
chemistry
;
genetics
;
immunology
;
Tuberculosis Vaccines
;
genetics
;
immunology
;
Vaccines, DNA
;
immunology
10.Immunological efficiency induced by HIV-1 p24 DNA combined with P24 protein.
Qingtao WANG ; Yuhai CHEN ; Shijuan GAO ; Wei JIANG ; Liping SONG ; Wenlin HUANG
Chinese Journal of Biotechnology 2011;27(5):773-780
New strategies to improve vaccine efficacy against human immunodeficiency virus type 1 (HIV-1) are still required. DNA vaccines, exhibiting potential advantages over conventional vaccines for their simplicity and versatility, can induce specific humoral and cellular immune responses. We developed a recombinant pVAX1 DNA vector carrying p24 gene of HIV-1. The results showed that pVAX1 mediated gene possessed the ability of effective expression in both transfected 293T cells and BALB/c mice. And pVAX1-p24 DNA prime and boost immunization can induce significant P24-specific humoral immune responses and cellular immune responses in BALB/c mice. Furthermore, immunization with pVAX1-p24 DNA prime and protein boost induced 7.3 to 8.0-fold greater p24-specific humoral responses than pVAX1-p24 DNA prime and boost, while the cellular immune responses induced by combined immunization was lower. The results suggested that pVAX1-p24 DNA and P24 protein vaccine is a promising HIV-1 vaccine, and the selections of the immunization strategies are important for the immunization results.
AIDS Vaccines
;
genetics
;
immunology
;
Animals
;
DNA
;
genetics
;
immunology
;
HEK293 Cells
;
HIV Core Protein p24
;
genetics
;
immunology
;
Humans
;
Immunization
;
Mice
;
Mice, Inbred BALB C
;
Vaccines, DNA
;
genetics
;
immunology